Milan, Italy, Innovation and cutting-edge technology to reduce Research and Development time and costs: InSilicoTrials, a company with broad expertise in Computational Modeling and Simulation, IT and cloud solutions for the healthcare sector, and Galileo Research established a partnership to apply in silico services for drug repurposing activities and provide mutual support in modeling and simulation activities.
R&D will be easier, cheaper, and faster
“In silico methods have been deeply changing the healthcare industry in the last few years”, says Luca Emili, CEO & Founder of InSilicoTrials. “The aim of this partnership with Galileo Research is to leverage modeling and simulation to innovate R&D. Our simulation platform can process a huge number of compounds in minutes instead of months, significantly reducing costs while increasing the knowledge on the safety of medicinal products, according to the guidelines of the regulatory bodies”.
“InSilicoTrials’s success is embedded in an exceptional ‘triple threat’ capability that includes unique online simulation products, a first-class network of scientific partners, and the computational and software engineering expertise to design and develop the in silico solution one needs. We believe in the powerful synergism of this partnership”, states Roberta Bursi, Executive VP R&D at InSilicoTrials.
“We are extremely proud to announce this new partnership with InSilicoTrials”, states Alberto Bresci, CEO of Galileo Research. “This collaboration offers an incredible opportunity for both partners. In silico approaches are expected to grow in the upcoming years, becoming highly recommended in terms of regulations, but they still need experimental supporting data. We believe this partnership can help R&D to maximize results by reducing costs, times, and attrition rates”.
“This is a great opportunity for both of us”, states Silvia Trasciatti, CSO of Galileo Research. “Galileo Research has always tried to minimize animal testing. Thanks to in silico methods provided by InSilicoTrials, we can continue to focus on the development of alternative procedures, and implement new strategies to assess safety and efficacy of drugs not only by the traditional experimental animal studies, but preferably through target-specific and mechanism-based biological investigations in vitro, also speeding up R&D”,
The Agreement was studied to combine the know-how and services of both companies, to exploit their strengths by using, on the one hand, Galileo Research’s experience, knowledge, and skills required to take drugs, medical devices, food supplements, and cosmetics on the market; on the other hand, the high competence of InSilicoTrials, with its broad expertise in Computational Modeling and Simulation, IT and cloud solutions for the life sciences sector.
The first step of this collaboration expects to reposition existing molecules in new therapeutic areas and indications (drug repurposing), thanks to InSilicoTrials’ solutions available on its cloud-based platform. Galileo Research will use the results gathered to develop proof of concept studies and in vitro testing, according to regulatory and scientific requirements.
About Galileo Research
Galileo Research is a preclinical Contract Research Organization (CRO) founded in 2011 as a spin-off of the R&D Division of Abiogen Pharma.
Galileo Research supports the discovery and GLP-compliant development of pharmaceuticals, medical devices, food and food supplements, chemicals, nutraceuticals, and cosmetics. Galileo Research also provides expertise in regulatory submissions and offers strategic skills in planning non-clinical testing programs to its Clients to reduce attrition rate and speed up the R&D process.
InSilicoTrials is an emerging startup founded in 2018 by a team of life sciences, cybersecurity, and digital innovation experts, which aims to innovate the healthcare sector. Today, the very long and expensive development, as well as the registration or certification processes for new drugs and medical devices, are becoming unsustainable. Modeling and simulation can reduce these costs up to 50% and greatly accelerate the go-to-market of new products while increasing their safety. InSilicoTrials collects validated computational models from international universities and integrates them with the solvers in a scalable online platform, where their interface and workflows are highly simplified, and therefore no specific computational knowledge is required. The fact that pharmaceutical companies, CROs and medical device producers can run the simulations on the platform in a pay-per-use way – without any need for software or IT infrastructure – can significantly reduce the cost and time of medical products development.